Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $12.3 million.

  • Evoke Pharma's Total Liabilities rose 2581.05% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year increase of 2581.05%. This contributed to the annual value of $10.5 million for FY2024, which is 863.29% up from last year.
  • According to the latest figures from Q3 2025, Evoke Pharma's Total Liabilities is $12.3 million, which was up 2581.05% from $11.7 million recorded in Q2 2025.
  • Evoke Pharma's 5-year Total Liabilities high stood at $12.3 million for Q3 2025, and its period low was $6.9 million during Q3 2021.
  • Over the past 5 years, Evoke Pharma's median Total Liabilities value was $9.0 million (recorded in 2024), while the average stood at $9.2 million.
  • Data for Evoke Pharma's Total Liabilities shows a peak YoY increase of 56916.78% (in 2021) and a maximum YoY decrease of 4451.54% (in 2021) over the last 5 years.
  • Over the past 5 years, Evoke Pharma's Total Liabilities (Quarter) stood at $7.0 million in 2021, then increased by 10.67% to $7.8 million in 2022, then grew by 24.22% to $9.6 million in 2023, then increased by 8.63% to $10.5 million in 2024, then grew by 17.23% to $12.3 million in 2025.
  • Its Total Liabilities was $12.3 million in Q3 2025, compared to $11.7 million in Q2 2025 and $10.5 million in Q1 2025.